Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted ...
UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...
UK-based biotechnology company Engitix Ltd. has raised a further $25 million from billionaire Michael Platt to help develop its therapies for cancer and fibrosis.
NewcelX Ltd. ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study ...
Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...
The utilization of biodegradable biomaterials as a therapeutic modality for musculoskeletal tissue regeneration has emerged as a promising avenue for ...
Prof. Liu Cong from the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences, along with collaborators, ...
Collagen is a vital aspect of skincare, and it has evolved from animal to marine to recombinant sources, each of which comes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback